Ozespa
Active substance: briakinumab
briakinumab
Centralised EU authorisationActive
Marketing holder: Abbott Laboratories Ltd.
Verified 2026-10-09 · EMA
- Source: EMA
- Countries with the substance registered: 1
Composition
Registration
- Registration number
- EMEA/H/C/002019
- Registration status
- Active
- ATC code
- L04AC09
Sources
- product · EMA · EMEA/H/C/002019 · Verified 2026-10-09
- registration_status · EMA · EMEA/H/C/002019 · Verified 2026-10-09
- ingredients.0 · EMA · EMEA/H/C/002019 · Verified 2026-10-09